Eli Lilly in charts: Obesity and diabetes portfolio drives growth in Q3 with Mounjaro +109% and Zepbound +185% Y/Y

Eli Lilly in charts: Obesity and diabetes portfolio drives growth in Q3 with Mounjaro +109% and Zepbound +185% Y/Y Continue reading Eli Lilly in charts: Obesity and diabetes portfolio drives growth in Q3 with Mounjaro +109% and Zepbound +185% Y/Y

Curbline Properties beats top-line and bottom-line estimates; updates FY outlook

Curbline Properties beats top-line and bottom-line estimates; updates FY outlook Continue reading Curbline Properties beats top-line and bottom-line estimates; updates FY outlook